New drug combo shows promise for rare blood cancer
NCT ID NCT02737046
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested a drug called belinostat combined with zidovudine (AZT) as a follow-up treatment for people with adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. The goal was to see if the combination could make cancer cells disappear from the blood. The study included 15 participants and tracked side effects and overall response to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.